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ABSTRACT
There is considerable interest in the use of bacter-
iophage vectors for mammalian cell gene transfer
applications, due to their stability, excellent safety
profile and inexpensive mass production. However,
to date, phage vectors have been plagued by
mediocre performance as gene transfer agents.
This may reflect the complexity of the viral infection
process in mammalian cells and the need to refine
each step of this process in order to arrive at an
optimal, phage-based gene transfer system.
Therefore, a flexible system was designed that
alowed for the introduction of multiple modifications
on the surface of bacteriophage lambda. Using this
novel method, multiple peptides were displayed
simultaneously from both the phage head and tail.
Surface head display of an ubiquitinylation motif
greatly increased the efficiency of phage-mediated
gene transfer in a murine macrophage cell line. Gene
transfer was further increased when this peptide
was displayed in combination with a tail-displayed
CD40-binding motif. Overall, this work provides a
novel system that can be used to rationally improve
bacteriophage gene transfer vectors and shows it
may be possible to enhance the efficiency of phage-
mediated gene transfer by targeting and optimizing
multiple steps within the viral infection pathway.
INTRODUCTION
Bacteriophage lambda has appealing characteristics as a
gene and vaccine delivery vector, which include a high
degree of physical stability, compatibility with rapid and
inexpensive production/puriﬁcation methods, genetic
tractability and inherent biological safety in mammalian
cells (1–3). In addition, the dimensions of the lambda
phage particles are broadly similar to those of many
mammalian viruses and recent structural evidence points
to a shared ancestry between tailed bacteriophages and
mammalian DNA viruses (4).
Lambda phage vectors have been successfully used to
transfer exogenous genes to mammalian cells, following
surface modiﬁcation of either the phage coat protein
(gpD) or the major tail protein (gpV) (5–8). Phage heads
contain between 405 and 420 copies of gpD (9), while the
phage tail consists of 32 rings, each containing six
subunits of gpV (10–12). Thus, both of these proteins
can be used to display foreign proteins or peptides at high
copy numbers on the surface of lambda phage particles.
Most attempts to enhance lambda phage-mediated gene
transfer to mammalian cells have concentrated on
optimizing the binding of phage particles to mammalian
cells (7,8,13,14). However, the eukaryotic cell poses
numerous barriers to phage-mediated gene transfer.
After receptor binding and internalization, phage must
gain access to the cytoplasm, uncoat and deliver their
DNA payload to the nucleus. Thus, the ultimate success
of phage-mediated gene transfer depends on the ability
to overcome multiple intracellular barriers. This is likely
to require the use of combination strategies that increase
the eﬃciency of each step involved in phage-mediated
gene transfer, including cell attachment, cytoplasmic
entry, endosomal escape, uncoating and nuclear import
(7,15,16).
This article reports the design and development of a
novel and tractable lambda-based vector that allows for
the facile generation of phage particles that display
multiple peptides or proteins of interest on their surface.
We hypothesized that this system could surmount current
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generating phage vectors that display a combination
of exogenous peptides each intended to circumvent a
separate barrier to eﬃcient phage gene delivery. This
article presents the ﬁrst example of single lambda phage
constructs incorporating multiple surface modiﬁcations
that, collectively, enhanced in vitro gene transfer to
mammalian cells.
METHODS
Lysogens
The D1180(luc) lysogen was a gift from Dr Mahito
Nakanishi and DNAVEC Corporation (6); D1180(luc)
contains a ﬁreﬂy luciferase gene under the transcriptional
control of the major human cytomegalovirus (CMV)
immediate-early promoter. Lysogen D1180 (Dam15 del
EcoRI-SacI cIts857 nin5 Sam100) is deﬁcient in gpD, the
S lysis gene, and contains a temperature-sensitive
mutation in the cI repressor. The E. coli lysogen host
(Top10, Invitrogen) is sup0, ensuring that neither Sam100
nor Dam15 are expressed.
Plasmid design
pTrc:gpD-Fusion and pTrc:gpD. The plasmids pTrc:gpD
and pTrc:gpD-Fusion were derived from pTrcHis
(Invitrogen) with the addition of a synthetic, codon-
optimized D gene as described (17). The D gene was
inserted as an NcoI to BamHI fragment, with subsequent
loss of the NcoI site. A linker sequence [G(SGGG)2
SGGT] was then added (BamHI to KpnI), to permit
insertion of DNA sequences encoding exogenous peptides
of interest between the sites KpnI and HindIII. The
plasmid pTrc:gpD was constructed with the addition of a
stop codon immediately after the codon optimized D gene.
pTrc:gpD-UBHA. A ubiquitinylation motif derived from
the Hepatitis A Virus (HAV) 3 protease [LGVKDDW
LLV; (18)] was constructed by overlapping PCR using the
primers: UBHAfor (50-AACCTGGGTACCTTAGGC
GTTAAAGATGACTGGTTGCTG-30) and UBHArev
(50-CAGGCTAAGCTTCTACACCAGCAACCAGTCA
TCTTTAAC-30; underlining denotes the translational
stop codon). The PCR product was digested with KpnI
and HindIII and cloned into pTrc:gpD-Fusion to create
pTrc:gpD-UBHA.
pTrcRSF:gpV-Fusion. The gpV expression plasmid was
constructed from pTrcHis. First, the truncated gpV gene
was PCR ampliﬁed from the phage genome using the
primers pVForA (50-AGCTCCATGGCGCCTGTACC
AAATCCTACAATG-30) and pV’RevLink (50-AGCTG
GATCCCCCTTTCACCACCGAGGTGC-30). The PCR
product was digested with BamHI and NcoI and cloned
into pTrcHis at the corresponding sites. A linker with the
sequence G(SGGG)8T was synthetically constructed by
GeneART (Regensburg, Germany) and inserted as a
BamHI to KpnI fragment. DNA sequences encoding the
exogenous fusion peptides of interest were then inserted as
KpnI to HindIII fragments, with the addition of a
translational stop codon at the end of each fusion
sequence.
The RSF plasmid origin of DNA replication and a
linked kanamycin resistance cassette from pRSF-1b
(Novagen) were inserted into the pTrc-based plasmid by
replacement of the pBR-based origin and ﬂanking
antibiotic cassette. This was achieved by PCR ampliﬁca-
tion of the corresponding DNA fragment from pRSF-1b
using the primers CDFDUETFOR (50-AGCTCCATGG
GAAGCACACGGTCACACTGCT-30) and CDFDUET
REV (50-AGCTGCATGCAAGTTAGCTCACTCATTA
GGGA-30). The PCR product was partially digested with
SphI and NcoI and then ligated with the promoter region
from the original pTrc-based, gpV expression plasmid
(which was isolated following digestion of the original
pTrc:gpV-Fusion plasmid with SphI and BspHI).
pTrcRSF:gpV-CD40. A DNA sequence encoding the
CD40 receptor-binding peptide, ATYSEFPGNLKP (19),
was subcloned from the parent plasmid pAT-043-CD40
using KpnI and HindIII digests and then cloned into
pTrcRSF:gpV-Fusion at the corresponding restriction
sites to create pTrcRSF:gpV-CD40.
Production ofpolyclonal antiserum
The production of the polyclonal anti-gpD antiserum has
been described (17). Polyclonal anti-gpV antiserum was
produced by transforming the plasmid pBAD:gpVtrunc
into Top10 E. coli (Invitrogen). Transformed bacteria were
grown to mid-log phase and then induced for 3h with
0.002% of L-arabinose. After expression, bacteria were
lysed with BugBuster (Novagen), treated with benzonase
and lysozyme and cleared by centrifugation. The lysate was
puriﬁed on a Ni–NTA matrix and fractions containing the
puriﬁed gpV protein were identiﬁed on immunoblot with
an anti-His antibody. SDS-PAGE puriﬁed fractions
containing the truncated gpV protein were submitted to
Sigma Genosys for the production of rabbit anti-gpV
antiserum. Antiserum reactivity was veriﬁed by immuno-
blot and aliquots were stored at  808C.
Phage production
Chemically competent lysogens of D1180 were trans-
formed with puriﬁed DNA plasmids of interest, and
transformants were then selected using media containing
the appropriate antibiotic. Single colonies were then
grown overnight at 328C with antibiotic selection, and the
resulting cultures were then used to inoculate 1l of fresh
antibiotic-containing medium the next day (at a dilution of
1:100). Cultures were grown at 328C with vigorous shaking
(300r.p.m.) until an OD600 of between 0.3 and 0.4 was
reached. Lysogens were induced by transferring the
bacteria to a water bath set between 51 and 538C, followed
byincubationwithgentleshakingfor20min.Afterthermal
induction, the cultures were vigorously shaken for an
additional 3h at 388C. Bacteria were then pelleted and
resuspended in phage suspension media (SM: 50mM
Tris-HCl, pH 7.5, 100mM NaCl, 10mM MgSO4, 0.01%
gelatin) and lysed with the addition of 10% chloroform.
After chloroform treatment, bacterial DNA was lysed with
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then cleared of cellular debris by low-speed centrifuga-
tion and phages were pelleted by ultracentrifugation at
110000g. Pelleted phage particles were subsequently
puriﬁed by cesium chloride equilibrium density gradient
centrifugation and phage were dialyzed against dialysis
buﬀer (10mM NaCl, 50mM Tris-HCl, pH 8.0, 10mM
MgCl2), prior to storage at 48C. Typical titers were
1 10
12p.f.u./ml.
Immunoblot analysis ofpurified phage
Phage was denatured and structural proteins separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Gels for the detection of gpD contained
between 15 and 20% polyacrylamide, while gels for gpV
contained between 12 and 15% polyacrylamide. Phage
proteins were detected by western blotting with
the appropriate primary antibody (rabbit polyclonal
antisera speciﬁc for either gpD or gpV, which were used
at dilutions of 1:1000 or 1:2000, respectively). Detection
of bound rabbit antibody was achieved by incubation with
a 1:3000 dilution of anti-rabbit HRP (Sigma) for 1h,
followed by detection with ECL-Plus Substrate
(Amersham Biosciences).
Detection ofCD40 expression on RAW 264.7cells
RAW 264.7 cells were purchased from the American Type
Culture Collection (ATCC) and maintained according to
ATCC recommendations. For detection of the CD40
receptor 1 10
6 cells were stained for 15min on ice with
1:200 of PE-CD40 or an appropriate isotype control
antibody (BD Pharmingen). After staining, cells were
washed with PBS, resuspended in FACS buﬀer, and
analyzed by ﬂuorescence-activated cell sorting using a
FACSCalibur instrument.
Luciferase assay forphage-mediated gene expression in
RAW 264.7cells
RAW 264.7 cells were plated at 1 10
5 cells/well in
12-well plates, 12h before the planned phage transduction.
After the 12-h incubation, the media was removed and
replaced with lambda phage (1 10
11p.f.u.) diluted in
1ml of serum-containing medium. Infection of cells was
centrifugally enhanced [1200g for 1h at 378C; ‘spinocula-
tion’ (20–22)] and cells were subsequently incubated
with the phage for 48h at 378C. Cells were then either
used for quantitative DNA PCR analysis (see below) or
used for luciferase assays. For the latter, cells were washed
with phosphate buﬀered saline (PBS) and then lysed in
30ml of Promega’s passive lysis buﬀer (PBL) for luciferase
analysis. Protein concentration in the lysates was deter-
mined by Bradford assay, and equal protein quantities
were used in luciferase assays, utilizing a luciferase assay
kit (Promega).
Quantitative DNA PCR assayfor phagegenome copies in
RAW 264.7cells
RAW 264.7 cells were transduced with lambda phage
particles as described above. At the end of the 48-h
incubation, cells were washed four times with PBS and
total genomic DNA was extracted using the Wizard
Genomic DNA Extraction Kit (Promega). Total genomic
DNA was quantitated spectrophotometrically and 10ng
was then used for QPCR analysis using a luciferase-
speciﬁc Taqman probe (50-CATTTCGCAGCCT
ACCGTGGTGTT-30) together with the reverse primer
TaqLucR (50-TTGCAACCCCTTTTTGGAAA-30) and
the forward primer TaqLucF (50-AACGTGAATTG
CTCAACAGTATGG-30). The ampliﬁcation conditions
comprised an initial denaturation step at 958C for
10min followed by 40 cycles at 958C for 15s and
608C for 1min. A standard curve for lambda DNA
quantitation was generated by using serially diluted
phage DNA and samples were analyzed with a Bio-Rad
iCycler. All standards and samples were assayed in
triplicate.
RESULTS
Incorporation of truncated gpVinto phage tails
We previously designed and evaluated a plasmid-based,
trans-complementation system that allowed the incorpora-
tion of recalcitrant peptides into the head of phage
lambda (17). We reasoned that a similar approach might
also permit the display of exogenous peptides on the major
tail protein, gpV.
Isolation of naturally occurring mutations in gpV
indicate that up to one-third of the carboxyl terminus is
unnecessary and can be deleted without adversely eﬀecting
tail assembly (23). Therefore, exogenous peptides have
been fused to the C-terminus of either full-length or
truncated gpV, and displayed on the tail of lambda
particles (24–26). Pilot experiments showed that a
truncated gpV protein bearing a hexahistidine tag was
eﬃciently incorporated into our phage particles (not
shown). Therefore, the truncated gpV gene was used in
all subsequent experiments.
Selection of peptidemotifs for displayon thehead and tail of
bacteriophagelambda particles
Successful gene transfer by bacteriophage vectors is likely
to depend on the circumvention of multiple intracellular
barriers to eﬃcient gene expression. Therefore, a vector
displaying multiple modiﬁcations, each intended to
address a distinct barrier to gene delivery, may result in
more eﬃcient gene transfer when compared to phage that
display only a single modiﬁcation on their surface.
Uncoating represents an important, but little studied,
aspect of phage-mediated gene transfer that may be
enhanced by the display of speciﬁc peptide motifs on the
phage surface. We were therefore intrigued by reports
that gene transduction by a number of mammalian
viruses can be improved in the presence of proteasome
inhibitors (27–29). This suggests that some viruses
may use ubiquitinylation and proteasomal degradation
to trigger head uncoating and genomic release. There is
also evidence that ubiquitinylation, especially mono-
ubiquitinylation, plays an important role in vesicular
traﬃcking (30) and that ubiquitin can serve as a signal
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mind, we set about displaying an ubiquitinylation motif
from the hepatitis A virus 3C protease (UBHA) on
the surface of lambda phage particles. To do this, the
ubiquitinylation motif (LGVKDDWLLV) was fused to
the C-terminus of gpD, and then displayed on phage
particles (17).
In order to test the feasibility of simultaneously
co-expressing two diﬀerent peptide motifs on the head
and tail of lambda phage particles, we selected a second,
receptor-binding peptide for display on the major tail
protein, gpV. For this purpose, we elected to display a
CD40-binding peptide (ATYSEFPGNLKP) that was
previously identiﬁed in our laboratory (19). We therefore
designed the plasmid pTrcRSF:gpV-CD40 to display this
peptide on the major lambda phage tail protein, gpV.
Generation ofbi-functional phage particles with
modifications toboth thehead andtail
The lysogen D1180(luc) was transformed with either
pTrc:gpD or pTrc:gpD-UBHA to produce phage particles
that displayed either wild-type gpD (Figure 1A) or a
modiﬁed gpD head protein fused to a ubiquitinylation
motif (Figure 1B). To produce phage particles that
displayed a modiﬁed gpV tail protein fused to a CD40-
binding peptide, the D1180(luc) lysogen was transformed
with pTrcRSF:gpV-CD40 and pTrc:gpD (Figure 1C).
Finally, bifunctional phage displaying both peptide
modiﬁcations were produced by dual transformation
with pTrc:gpD-UBHA and pTrcRSF:gpV-CD40 into
D1180(luc) lysogens (Figure 1D). Phage particles were
then produced following lytic induction of the lysogen,
and CsCl density-gradient-puriﬁed phage particles were
analyzed by western blot with antisera speciﬁc for gpD or
gpV. As expected, introduction of pTrc:gpD-UBHA into
the lysogen resulted in the generation of progeny phage
particles that had full replacement of wild-type gpD
head protein with gpD-UBHA (Figure 2; top panel).
Similarly, introduction of the expression plasmid for
Figure 1. Expression plasmids for the production of bi-functional
phage. Production of bi-functional phage displaying peptide modiﬁca-
tions on both gpD and gpV was achieved by transformation of lambda
lysogens with a series of compatible plasmid expression constructs.
(A) pTrc:gpD for the expression of unmodiﬁed wild-type gpD.
(B) pTrc:gpD-UBHA for the expression of gpD displaying a ubi-
quitinylation motif from the hepatitis A virus 3C protease (UBHA).
(C) pTrc:gpD co-transformed with pTrcRSF:gpV-CD40 for the
expression of wild-type gpD in conjunction with gpV displaying a
CD40-binding peptide (CD40). (D) pTrc:gpD-UBHA co-transformed
with pTrcRSF:gpV-CD40 for the simultaneous expression of
gpD-UBHA and gpV-CD40.
Figure 2. Co-transformation of gpD-UBHA and gpV-CD40 expression
plasmids into lysogens yields bi-functional phage displaying both
peptide fusions. The plasmid pTrc:gpD-UBHA and the plasmid
pTrcRSF:gpV-CD40 were co-transformed into lambda lysogens.
After lytic induction, phage were puriﬁed by CsCl density gradient
centrifugation and analyzed. (A) Phage (5 10
8p.f.u.) were loaded on a
12% polyacrylamide gel, subjected to SDS-PAGE and transferred
to nitrocellulose. Immunoblot analysis was then performed using an
anti-gpD rabbit polyclonal antiserum. This revealed full replacement of
gpD with gpD-UBHA in phage produced from lysogens carrying the
pTrc:gpD-UBHA plasmid. The molecular weight of gpD is  12kDa
and of gpD-UBHA is  16kDa. (B) Phage (5 10
8p.f.u.) were loaded
on a 12% polyacrylamide gel, subjected to SDS-PAGE and transferred
to nitrocellulose. Immunoblot analysis was then performed with an
anti-gpV polyclonal antiserum. This revealed that the phage expressing
the gpV-CD40 fusion protein contained roughly a 1:1 ratio of wild-
type gpV and recombinant gpV-CD40. The projected molecular
weights are  30kDa for wild type gpV and  27kDa for recombinant
gpV-CD40 (Note that the recombinant gpV fusion protein is based on
a truncated form of gpV, and is therefore smaller than its wild-type
counterpart).
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progeny phage particles that had  50% replacement of
wild-type gpV tail protein with the gpV-CD40 fusion
protein (Figure 2; lower panel). Full replacement of wild-
type gpV on the phage tail was not expected, since the
lambda lysogen contains a functional wild-type gpV gene.
In contrast, the lysogen contains an amber-mutated gpD
gene that permits full replacement of gpD by exogenously
expressed recombinant gpD, in host cells that lack
the amber suppressor tRNA. In addition to the partial
replacement of gpV that is evident in Figure 2 (lower
panel), it can also be appreciated that the gpV-CD40
fusion protein is smaller than the endogenous gpV protein.
This is because we used the truncated form of gpV to
construct the gpV-CD40 fusion (see Materials and
methods section).
Displayoftwodistinctpeptidemodificationsonthesurfaceof
lambda phageresults in an enhancement of phage-mediated
gene transfer
We hypothesized that phage particles displaying both a
CD40-binding motif on the phage tail and an ubiquitiny-
lation motif on the phage head would be capable of
mediating more eﬃcient gene transfer in CD40-positive
mammalian cells, when compared to unmodiﬁed phage
particles or phage particles that displayed only a single
capsid modiﬁcation.
In order to test this prediction, we performed in vitro
gene transfer experiments using the RAW 264.7 cell line.
This murine macrophage cell line retains key properties of
primary macrophages, including (i) cell surface expression
of modest levels of CD40 and (ii) the ability to take up
exogenous particles and macromolecules by phagocytosis
(32–35). The phagocytic competence of RAW cells may be
important since phagocytosis has been proposed to
represent the major mechanism by which lambda phage
vectors transduce cells in vivo (36).
RAW 264.7 cells were exposed to luciferase-encoding
phage particles at high, intermediate and low multiplicities
of infection (MOI¼1 10
6,3  10
5 or 1 10
5, respec-
tively). Forty-eight hours later, the cells were washed
extensively and extracts were prepared for analysis of
luciferase expression levels.
Unmodiﬁed phage particles (gpD) and particles which
displayed only the CD40-binding peptide (gpV-CD40) did
not mediate detectable levels of luciferase gene expression
when compared to control cell lysates (Figure 3; note that
there is a modest but non-statistically signiﬁcant trend
towards increased gene transduction in the case of the
gpV-CD40 phage, at the high-dose level).
In contrast, phage that displayed the ubiquitinylation
motif (UBHA) on their surface were able to successfully
mediate gene transfer in RAW 264.7 cells, leading to
luciferase levels that were roughly 10-fold greater than
background, at the high dose level (P50.01); gene transfer
was not signiﬁcantly above background at the intermedi-
ate dose level. Very similar results were obtained following
exposure of cells to a simple mixture of phage particles
that displayed either gpV-CD40 or gpD-UBHA on their
surface (groups designated as ‘gpD-UBHAþgpV-CD40’
in Figure 3).
Gene transfer was further enhanced (by  2-fold)
when the UBHA motif was co-displayed on the
phage surface together with the CD40-binding peptide
(groups designated as ‘gpD-UBHA/gpV-CD40’ in
Figure 3). At the intermediate dose level, this result
achieved statistical signiﬁcance (P50.01) when compared
either to gpD-UBHA phage alone or to the mixture of
gpD-UBHAþgpV-CD40 phage.
DisplayoftheCD40-bindingpeptideonthesurfaceoflambda
phageresults in an enhancement ofphage-mediated DNA
uptakeinto cells
To further examine the eﬀect of displaying the CD40-
binding peptide on the phage surface, the eﬃciency of
phage genome uptake into cultured RAW 264.7 cells was
analyzed. The cells were conﬁrmed to express CD40 by
ﬂow cytometric analysis (Figure 4B), and were then
exposed to each of the phage constructs at a ﬁxed MOI
(1 10
6). Forty-eight hours later, cells were washed
thoroughly, and lysates prepared. Analysis of lambda
genome copy number in lysates from transduced cells
revealed that DNA copy number was slightly, but
signiﬁcantly (P50.05), greater in cells which were
transduced with phage particles that displayed gpV-
CD40 versus unmodiﬁed phage (Figure 4A). Lambda
genome copy number was further elevated in cells
which were transduced with phage particles that displayed
gpD-UBHA plus gpV-CD40 versus phage particles that
displayed either gpD-UBHA or gpV-CD40 alone
(Figure 4A; P50.001). This suggests that surface display
of the CD40-binding peptide enhances phage-mediated
gene transfer at the level of either phage binding or
internalization (leading to an increase in the number of
phage genome copies in the cell).
Analysis of phage genome copies in transduced cells
also revealed that surface display of the UBHA peptide
did not lead to an increase in the number of phage genome
copies per cell, when compared to unmodiﬁed phage
particles (Figure 4A; compare gpD and gpD-UBHA).
Since surface display of the UBHA peptide resulted in a
profound increase in phage-mediated gene expression
(Figure 3), we conclude that surface display of the
UBHA peptide enhances phage-mediated gene transfer
at a post-internalization step. This may reﬂect an eﬀect on
intracellular traﬃcking of phage particles, on phage
uncoating or on another ubiquitin/proteasome-dependent
pathway (29).
DISCUSSION
Multiple phage capsid proteins suitable for peptide display
have been identiﬁed in both lambda and M13. Despite
this, simultaneous display from two or more protein
platforms has rarely been described, even in the more
widely studied ﬁlamentous phage display system (37–40).
Recently, a bifunctional ﬁlamentous phage intended for
delivering biological agents was described (40). The phage
combined an integrin-targeting moiety at pIII with a
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their phage in vitro for receptor speciﬁc cell binding and
internalization. In addition, they complexed their phage
with quantum dots and then demonstrated tumor-speciﬁc
accumulation after intravenous injection in mice. Despite
these few successes, the design of bifunctional phage
remains underexplored and underutilized. In 1996, Dunn
proposed a bifunctional lambda phage combining gpD
and gpV display, yet, until now, a bifunctional lambda
phage has never been described (8).
The experiments reported here resulted in the simulta-
neous co-display of two diﬀerent peptide modiﬁcations on
the head and tail of lambda phage particles, as transla-
tional fusions to gpD and gpV, respectively. In both cases,
a high copy number of the displayed peptide was achieved
(full replacement, or roughly 400 copies/phage particle in
the case of the gpD fusion protein and partial replace-
ment, or roughly 100 copies/phage particle in the case of
the gpV fusion protein). Moreover, because the gpD and
gpV expression plasmids described here are compatible
with the previously described, CDF-origin-based plasmid,
pTrcCDF:gpD-Fusion (17), it should be possible to
introduce up to three modiﬁcations to a single phage
particle in the future (two to gpD, and one to gpV).
The long-term goal of our experiments is to develop a
bacteriophage lambda vector system that is capable of
mediating eﬃcient gene transfer into mammalian cells.
As a ﬁrst step towards this goal, we evaluated phage-
mediated gene transfer in a murine macrophage cell line
using recombinant lambda phage particles that encoded
Figure 3. Display of two distinct modiﬁcations on the phage capsid results in a dose-dependent enhancement of phage-mediated gene transfer in
RAW 264.7 cells. RAW 264.7 cells were incubated with phage particles at the indicated MOIs (high, intermediate and low doses corresponding
respectively to 1 10
6,3  10
5 or 1 10
5p.f.u./cell). After an initial centrifugal enhancement step (1200g, 1h), cells were incubated with the phage
for 48h at 378C. Cells were then washed, lysed, and analyzed for luciferase expression. Luciferase assays were performed using equal total protein
quantities for each sample. Unmodiﬁed phage particles (gpD) and particles which displayed only the CD40-binding peptide (gpV-CD40) did not
mediate levels of luciferase gene expression that were signiﬁcantly above background, when compared to control cell lysates; a modest but non-
statistically signiﬁcant trend towards increased gene transduction was observed in the case of the gpV-CD40 phage at the high dose level. In contrast,
surface display of gpD-UBHA produced a 10-fold increase in gene expression above baseline at the high dose level (P50.01, when compared to
unmodiﬁed phage) and a modest (1.7-fold) but non-statistically signiﬁcant increase at the intermediate dose level. Gene transfer eﬃciency was also
tested in cells that were exposed to a simple mixture of phage particles that displayed either gpV-CD40 or gpD-UBHA on their surface (designated as
‘gpD-UBHAþgpV-CD40’). In this case, the full-indicated dose of each phage was added to the cells (i.e. at the high dose levels, cells received
1 10
6p.f.u. of gpV-CD40 phage plus 1 10
6p.f.u. of gpD-UBHA phage). Exposure of cells to this mixture of phage particles resulted in levels of
gene transfer that were very similar to those elicited by the gpD-UBHA phage alone. There was a statistically signiﬁcant 7-fold increase in gene
transfer eﬃciency at the high dose group level (P50.01, compared to unmodiﬁed phage) and a modest (2-fold) but non-statistically signiﬁcant
increase at the intermediate dose level. Finally, cells were exposed to the bi-functional phage, which displayed both gpV-CD40 with gpD-UBHA on
its surface (designated gpD-UBHA/gpV-CD40). This resulted in a further increase in phage-mediated gene expression (by  2-fold) when compared to
the gpD-UBHA head modiﬁcation alone, or to the simple mixture of gpD-UBHA and gpV-CD40 phage, at both the high and intermediate dose
levels. At the intermediate dose level, this result achieved statistical signiﬁcance (P50.01, compared to cells exposed either to gpD-UBHA phage
alone or to the mixture of gpD-UBHAþgpV-CD40 phage). At the high dose level, the result achieved statistical signiﬁcance when compared to the
mixture of gpD-UBHAþgpV-CD40 phage (P50.05), but not when compared to the gpD-UBHA phage alone. Statistical analysis was performed
using one-way ANOVA with Tukey’s post-test; signiﬁcance was taken as P50.05.
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the surface display of an ubiquitinylation motif resulted in
a profound enhancement of phage-mediated gene transfer.
The ubiquitinylation motif may enhance phage-
mediated gene transfer as a result of proteasome-mediated
uncoating of the phage particle, or because of eﬀects on
the intracellular traﬃcking of internalized phage particles
(30), and possible localization of internalized phage
particles to multi-vesicular bodies (31), or due to eﬀects
on other intracellular pathways (29). It is noteworthy that
certain mammalian viruses such as Vesicular Stomatitis
Virus (VSV) rely on multi-vesicular bodies for endosomal
escape and eﬃcient infection of host cells (41,42).
Attempts to resolve the mechanism by which the displayed
ubiquitinylation motif enhances phage-mediated gene
transfer were inconclusive, since the well-characterized
proteasome inhibitors MG-132 and lactacystin proved
toxic to the RAW 264.7 cells, even at the minimum
eﬀective dose. Thus, future studies will be needed to
investigate the mechanism by which the ubiquitinylation
motif enhances phage-mediated gene transfer.
Our proof-of-principle experiments also evaluated
whether the simultaneous display of two diﬀerent mod-
iﬁcations on the phage surface may further enhance
phage-mediated gene transfer. To do this, we generated
luciferase-encoding phage particles that displayed a
receptor (CD40)-binding peptide on their major tail
protein (gpV) in addition to the ubiquitinylation motif
on their major head protein (gpD). These bifunctional
phage particles were able to mediate an enhanced
eﬃciency of gene transfer into a cultured murine macro-
phage cell line, when compared to phage particles that
displayed only a single peptide moiety on their surface.
This eﬀect was dose-dependent, with higher levels of gene
transfer being detected when larger amounts of phage
were added to cells. Furthermore, co-display of both
motifs on the same phage particle was required for the
observed enhancement of phage-mediated gene transfer;
gene transfer eﬃciency was signiﬁcantly improved when
compared to a simple mixture of gpD-UBHA phage plus
gpV-CD40 phage. Thus, the enhanced gene transfer eﬀect
by the dual-display construct cannot be attributed to a
trans-eﬀect.
Overall, the results reported provide strong support for
the notion that it may be possible to rationally improve
the eﬃciency of phage-mediated gene transfer by display-
ing several diﬀerent peptides on the phage surface. In the
future it should be possible to introduce and test other
modiﬁcations with the intention of eventually designing a
highly eﬃcient phage-based gene delivery vector.
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Figure 4. Display of a CD40-targeting peptide on the phage capsid
results in an enhancement of phage-mediated DNA uptake transfer
into RAW 264.7 cells. (A) RAW 264.7 cells were incubated with phage
particles at an MOI of 1 10
6p.f.u.. After an initial centrifugal
enhancement step (1200g, 1h), cells were incubated with the phage
for 48h at 378C, and then washed and lysed. Analysis of lambda genome
copy number was conducted using 10ng of total input cellular DNA
prepared from the cell lysates. DNA copy number was slightly, but
signiﬁcantly (P50.05), greater in cells which were transduced with
phage particles that displayed gpV-CD40 versus unmodiﬁed phage (gpD).
The bi-functional phage, combining gpV-CD40 with gpD-UBHA, further
increased lambda genome copy number (P50.001, when compared to
phage displaying gpD-UBHA or gpV-CD40 alone). Surface display of
the UBHA peptide did not lead to a statistically signiﬁcant increase in
the number of phage genome copies per cell, when compared to
unmodiﬁed phage particles (gpD). Statistical analysis was performed
using one-way ANOVA with Tukey’s post-test; signiﬁcance was taken
as P50.05. (B) RAW 264.7 cells were stained with an anti-CD40-PE
antibody or an isotype control antibody, and stained cells were analyzed
by ﬂow cytometry. The darkly shaded curve represents staining with
the isotype control antibody, and the unshaded curve represents staining
of cells with the CD40-speciﬁc antibody.
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